Patent · US Active

Peptide compounds exhibiting glucagon antagonist and GLP-1 agonist activity

US8980830B2 · kind B2 · utility

15Cited by

15References

22Claims

0Family size

Assignee

INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION · US

Inventors

Richard D. DiMarchi · Carmel, US
Bin Yang · Waltham, US
Chenguang Ouyang · Bloomington, US

Key dates

Filing date	Oct 27, 2008
Grant date	Mar 17, 2015
Priority date	—
Expiry date	Mar 12, 2030

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K38/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Glucagon analogs are disclosed that exhibit both glucagon antagonist and GLP-1 agonist activity. In one embodiment, the glucagon antagonist/GLP-1 agonist comprises a modified amino acid sequence of native glucagon, in which the first one to five N-terminal amino acids of native glucagon is deleted and in which the alpha helix is stabilized.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.